Proscia expands into the international diagnostic pathology market

Proscia has expanded into the international diagnostic pathology market to meet the growing needs of laboratories and cancer patients worldwide. The company has added the leadership of Arun Ananthapadmanabhan as Executive Vice President, Global Growth, to manage commercial operations for its international market. Proscia’s accelerated global focus follows the company’s November announcement that it received CE Mark for its Concentriq Dx solution for use in primary diagnosis.